Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Expert Opinion on Pharmacotherapy
|
February 19, 2010
Laromustine (cloretazine)
Norbert Vey, Frank Giles
Expert Review of Anticancer Therapy
|
March 1, 2006
Cloretazine for the treatment of acute myeloid leukemia
Norbert Vey, Frank Giles
Cancer Journal (Sudbury, Mass.)
|
April 25, 2006
Novel agents in acute myeloid leukemia
Ahmed Aribi, Farhad Ravandi, Frank Giles
Leukemia & Lymphoma
|
April 10, 2008
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells
David J Adams, Marit L Sandvold, Finn Myhren, et al.
Oncotarget
|
July 3, 2018
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review
Young Kwang Chae, Lauren Chiec, Scott K Adney, et al.
Blood
|
July 22, 2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis, Patrick Brown, B Douglas Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia
Sieghart Sopper, Satu Mustjoki, Deborah White, et al.
Journal of Cancer Research and Clinical Oncology
|
May 29, 2017
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
Juan Luis Steegmann, Dolors Colomer, Maria-Teresa Gómez-Casares, et al.
Journal of Cancer Research and Clinical Oncology
|
October 25, 2017
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
Juan Luis Steegmann, Dolors Colomer, Maria-Teresa Gómez-Casares, et al.
Plant Disease
|
October 28, 2025
Grove-First: A Generalizable Framework to Evaluate Translational Solutions to Citrus Greening and Other Perennial Crop Diseases
Michelle L Heck, Nicholas Larson, Guilherme Locatelli, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Expert Opinion on Pharmacotherapy
|
February 19, 2010
Laromustine (cloretazine)
Norbert Vey, Frank Giles
Expert Review of Anticancer Therapy
|
March 1, 2006
Cloretazine for the treatment of acute myeloid leukemia
Norbert Vey, Frank Giles
Cancer Journal (Sudbury, Mass.)
|
April 25, 2006
Novel agents in acute myeloid leukemia
Ahmed Aribi, Farhad Ravandi, Frank Giles
Leukemia & Lymphoma
|
April 10, 2008
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells
David J Adams, Marit L Sandvold, Finn Myhren, et al.
Oncotarget
|
July 3, 2018
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review
Young Kwang Chae, Lauren Chiec, Scott K Adney, et al.
Blood
|
July 22, 2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis, Patrick Brown, B Douglas Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia
Sieghart Sopper, Satu Mustjoki, Deborah White, et al.
Journal of Cancer Research and Clinical Oncology
|
May 29, 2017
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
Juan Luis Steegmann, Dolors Colomer, Maria-Teresa Gómez-Casares, et al.
Journal of Cancer Research and Clinical Oncology
|
October 25, 2017
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
Juan Luis Steegmann, Dolors Colomer, Maria-Teresa Gómez-Casares, et al.
Plant Disease
|
October 28, 2025
Grove-First: A Generalizable Framework to Evaluate Translational Solutions to Citrus Greening and Other Perennial Crop Diseases
Michelle L Heck, Nicholas Larson, Guilherme Locatelli, et al.
Page
of 1